From Molecular Mechanisms to Management: Advances in Diabetic Retinopathy and Diabetic Macular Edema
Year: 2026
Type: article
Abstract: Diabetic retinopathy (DR) is a major microvascular complication of diabetes mellitus (DM) and a leading cause of vision loss worldwide. Several risk factors have been implicated in the development and progression of DR, such as longer duration of diabetes, poor glycemic control, hypertension, dyslipidemia, renal impairment, and smoking. Diabetic macular edema is the main cause of visual impairment in patients with diabetic retinopathy. It is defined by retinal thickening from fluid leakage into the retina and can be visualized with optical coherence tomography (OCT). At the molecular level, chronic hyperglycemia triggers several pathogenic mechanisms, including oxidative stress, inflammation, advanced glycation end product formation, protein kinase C activation, and dysregulated vascular endothelial growth factor (VEGF) signaling, leading to blood–retinal barrier breakdown, microvascular dysfunction, and retinal neurodegeneration. Current therapeutic approaches include laser photocoagulation, intravitreal anti-VEGF agents, and corticosteroids, with ongoing research into novel interventions targeting senolytic agents, integrin antagonists, inhibitors of vascular adhesion protein-1, anti-inflammatory therapies targeting interleukin-6 (IL-6) signaling, and plasma kallikrein inhibitors. This review synthesizes the recent evidence on DR epidemiology, risk factors, pathophysiology, and treatment, highlighting the need for comprehensive risk-based screening and multidisciplinary management to mitigate the growing burden of diabetic eye disease.
Institution: Nazarbayev University
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Keywords: diabetic retinopathy, diabetic macular edema, diabetes mellitus, hyperglycemia, oxidative stress, inflammation, advanced glycation end products, protein kinase C, VEGF signaling, blood-retinal barrier breakdown, retinal neurodegeneration, risk factors, laser photocoagulation, anti-VEGF therapy, corticosteroids, senolytics, integrin antagonists, interleukin-6, plasma kallikrein inhibitor, diabetic retinopathy screening
Open Access status: gold
Estimated APC paid: $3,499
OpenAlex ID: W7234585085
